lightspring
Lightspring / Shutterstock.com
20 May 2020AmericasPaul Williams

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

The US Chamber of Commerce has published its  International IP Index 2020, a map of the IP ecosystems of 53 economies, representing over 90% of global gross domestic product (GDP). The index aims to provide a snapshot of each economy’s overall IP ecosystem by evaluating its IP framework across 50 indicators, selected to represent the most effective IP systems.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

More on this story

Big Pharma
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.

More on this story

Big Pharma
15 May 2020   The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
Big Pharma
28 May 2020   A new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative as favouring Big Pharma over small businesses, particularly when it comes to IP.
Europe
11 June 2020   The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.